When was Eisai founded?

Eisai was founded in 1941 and raised its 1st funding round 66 years after it was founded.

Where is Eisai located?

Eisai is headquartered in Jakarta, Indonesia. It is registered at 93/1 ยูนิต 603-604, 6 จีพีเอฟ วิทยุ ทาวเวอร์ เอ, วิทยุ, ลุมพินี, เขตปทุมวัน, กรุงเทพมหานคร.

How many employees does Eisai have?

As of Sep 30, 2026, the latest employee count at Eisai is 14.

Is Eisai a funded company?

Eisai is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 15, 2007.

When was the latest funding round of Eisai?

Eisai's latest funding was a $***** Grant (prize money) round on Jan 28, 2025, with participation from 1 investor.

Where does Eisai rank among its competitors?

Eisai ranks 20th amongst 1835 active competitors, of which 94 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Eisai?

Eisai's top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Eisai - 2026 Company Profile, Team, Funding & Competitors

Eisai is a public company based in Jakarta (Indonesia), founded in 1941. It operates as a Developer of drugs for oncology and neurological disorders. Eisai has raised an undisclosed amount in funding. The company has 1835 active competitors, including 94 funded and 204 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.

Company Details

Developer of drugs for oncology and neurological disorders. The company's products include ciphex/Pariet (rabeprazole) for Gastroesophageal reflux disease, Actonel (risedronic acid) for Osteoporosis, Aloxi (palonosetron) for Chemotherapy-induced nausea and vomiting, Aricept (donepezil) for Alzheimer's Disease, Banzel/Inovelon (rufinamide) for seizures related to Lennox for gastaut syndrome, Belviq (lorcaserin) for obesity, Fragmin (dalteparin) for deep vein thrombosis and pulmonary embolism, and more.

Website: www.eisai.com/index.html
Social
Phone Number: +81 **********
Registered Address: 93/1 ยูนิต 603-604, 6 จีพีเอฟ วิทยุ ทาวเวอร์ เอ, วิทยุ, ลุมพินี, เขตปทุมวัน, กรุงเทพมหานคร

Key Metrics

Founded Year

1941

Location

Jakarta, Indonesia

Stage

Public

Latest Funding Round

Grant (prize money), Jan 28, 2025, $*****

Investors

Petrillo Capital & 4 more

Ranked

20^th among 1835 active competitors

Employee Count

14 as on Sep 30, 2026

Investment & Acquisitions

Beren Therapeutics & 11 more

Similar Companies

AbbVie & 1863 more

Exit Details

Public

View Eisai's full profile

Eisai is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED CIN: U21002AP2007PTC053247 , India, Active	Mar 22, 2007	₹100 - ₹500 Cr (As on Mar 31, 2025)	-
EISAI (THAILAND) MARKETING CIN: 0105532098891 , Thailand, Active	Oct 17, 1989	$50M - $100M (As on Dec 31, 2023)	-

Eisai got listed on Sep 14, 1961.

Click here to take a look at Eisai's IPO in detail

Eisai has raised funding over 3 rounds. Its first funding round was on Aug 15, 2007. Its latest funding round was a Grant (prize money) round on Jan 28, 2025 for $*****. 1 investor participated in its latest round. Eisai has 5 institutional investors.

Here is the list of recent funding rounds of Eisai:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 28, 2025	6273834	Grant (prize money)	5321752	7212353	8212418	9119689
Mar 01, 2011	6418213	Grant (prize money)	5185197	4299515	2485486	HHS
Aug 15, 2007	3728249	Grant (prize money)	5664175	7716536	1683308	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Eisai's funding rounds and investors

Eisai's employee count trend

Eisai has 14 employees as of Sep 26. Here is Eisai's employee count trend over the years:

Uncover Eisai's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eisai include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Eisai, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100
20th	Eisai 1941, Jakarta (Indonesia), Public	Developer of drugs for oncology and neurological disorders	-	Petrillo Capital, Plexus Ventures & 3 others	61/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Eisai's competitors? Click here to see the top ones

Eisai has made 9 investments in companies including Beren Therapeutics and Seed Therapeutics. Eisai has also acquired 3 companies including AkaRx and MGI Pharma.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jun 10, 2026	Investments	Beren Therapeutics	2020	Bonn (Germany)
Aug 2025	Investments	Seed Therapeutics	2019	New York City (United States)
Aug 2024	Investments	Seed Therapeutics	2019	New York City (United States)